These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25444231)

  • 1. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review.
    Guedes M; Esperança A; Pereira AC; Rego C
    Rev Port Cardiol; 2014 Nov; 33(11):727-32. PubMed ID: 25444231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
    Zhao L; Cao L; Zhao TY; Yang X; Zhu XX; Zou HJ; Wan WG; Xue Y
    Chin Med J (Engl); 2020 Apr; 133(8):982-993. PubMed ID: 32106120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
    Franchi C; Salerno F; Conca A; Djade CD; Tettamanti M; Pasina L; Corrao S; Marengoni A; Marcucci M; Mannucci PM; Nobili A;
    Eur J Intern Med; 2014 Nov; 25(9):847-52. PubMed ID: 25439099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
    Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
    Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of uric acid and allopurinol therapy in cardiovascular disease].
    Linhart A; Rob D
    Vnitr Lek; 2015 May; 61(5):421-30. PubMed ID: 26075851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
    Akkineni R; Tapp S; Tosteson AN; Lee A; Miller KL; Choi HK; Zhu Y; Albert DA
    J Rheumatol; 2014 Apr; 41(4):739-48. PubMed ID: 24584921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.
    Mercuro G; Vitale C; Cerquetani E; Zoncu S; Deidda M; Fini M; Rosano GM
    Am J Cardiol; 2004 Oct; 94(7):932-5. PubMed ID: 15464681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.
    Bletsa E; Paschou SA; Tsigkou V; Stampouloglou PK; Vasileiou V; Kassi GN; Oikonomou E; Siasos G
    Hormones (Athens); 2022 Dec; 21(4):599-610. PubMed ID: 36197637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.
    Pavlusova M; Jarkovsky J; Benesova K; Vitovec J; Linhart A; Widimsky P; Spinarova L; Zeman K; Belohlavek J; Malek F; Felsoci M; Kettner J; Ostadal P; Cihalik C; Spac J; Al-Hiti H; Fedorco M; Fojt R; Kruger A; Malek J; Mikusova T; Monhart Z; Bohacova S; Pohludkova L; Rohac F; Vaclavik J; Vondrakova D; Vyskocilova K; Bambuch M; Dostalova G; Havranek S; Svobodová I; Dusek L; Spinar J; Miklik R; Parenica J
    Clin Cardiol; 2019 Aug; 42(8):720-727. PubMed ID: 31119751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond gout: uric acid and cardiovascular diseases.
    Agabiti-Rosei E; Grassi G
    Curr Med Res Opin; 2013 Apr; 29 Suppl 3():33-9. PubMed ID: 23611366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
    Kanbay M; Afsar B; Siriopol D; Dincer N; Erden N; Yilmaz O; Sag AA; Kuwabara M; Cherney D; Rossignol P; Ortiz A; Covic A
    Angiology; 2020 Apr; 71(4):315-323. PubMed ID: 32000517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia and cardiovascular disease risk.
    Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
    Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
    JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.